These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 24906422)

  • 1. Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
    Schnell D; Buschke S; Fuchs H; Gansser D; Goeldner RG; Uttenreuther-Fischer M; Stopfer P; Wind S; Petersen-Sylla M; Halabi A; Koenen R
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):267-75. PubMed ID: 24906422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study.
    Wiebe S; Schnell D; Külzer R; Gansser D; Weber A; Wallenstein G; Halabi A; Conrad A; Wind S
    Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):461-469. PubMed ID: 27436099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
    Narasimhan NI; Dorer DJ; Davis J; Turner CD; Marbury TC; Sonnichsen D
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):341-8. PubMed ID: 24934866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning.
    Nakamaru Y; Kakubari M; Yoshida K; Akimoto M; Todorovic V; Greis T; Kondo K
    Clin Ther; 2020 Aug; 42(8):1467-1482.e4. PubMed ID: 32800532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
    Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
    Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
    Zhao Q; Iyer GR; Verhaeghe T; Truyen L
    J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of linagliptin in subjects with hepatic impairment.
    Graefe-Mody U; Rose P; Retlich S; Ring A; Waldhauser L; Cinca R; Woerle HJ
    Br J Clin Pharmacol; 2012 Jul; 74(1):75-85. PubMed ID: 22242621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
    Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
    Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
    Urva S; Quinlan T; Landry J; Ma X; Martin JA; Benson CT
    Clin Pharmacokinet; 2022 Jul; 61(7):1057-1067. PubMed ID: 35674880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
    Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
    Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours.
    Wind S; Schmid M; Erhardt J; Goeldner RG; Stopfer P
    Clin Pharmacokinet; 2013 Dec; 52(12):1101-9. PubMed ID: 23813493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
    Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
    Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment.
    Grasela DM; Christofalo B; Kollia GD; Duncan G; Noveck R; Manning JA; LaCreta FP
    Pharmacotherapy; 2000 Jun; 20(6 Pt 2):87S-94S. PubMed ID: 10850525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects.
    Flanagan S; Ong V; Marbury T; Jandourek A; Gandhi RG; Sandison T
    Pharmacotherapy; 2024 Jun; 44(6):435-443. PubMed ID: 38840536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
    Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
    Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment.
    Kropeit D; McCormick D; Erb-Zohar K; Moiseev VS; Kobalava ZD; Stobernack HP; Zimmermann H; Rübsamen-Schaeff H
    Br J Clin Pharmacol; 2017 Dec; 83(12):2678-2686. PubMed ID: 28722153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
    Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
    Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
    Baird-Bellaire S; Behrle JA; Parker VD; Patat A; Paul J; Nichols AI
    Clin Ther; 2013 Jun; 35(6):782-94. PubMed ID: 23623756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment.
    Taylor L; Crockett J; Tayo B; Morrison G
    J Clin Pharmacol; 2019 Aug; 59(8):1110-1119. PubMed ID: 30921490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment.
    Sekar V; Spinosa-Guzman S; De Paepe E; Stevens T; Tomaka F; De Pauw M; Hoetelmans RM
    Clin Pharmacokinet; 2010 May; 49(5):343-50. PubMed ID: 20384396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.